## Answer
(model generated chain of thought explanation)

To answer this question, let's break down the key components:

1. **Vaccine type**: The vaccine contains polyribosylribitol phosphate conjugated to a toxoid carrier.
2. **Conjugation method**: This is an immunization technique where a polysaccharide (in this case, polyribosylribitol phosphate) is linked to a toxin (toxoid). This approach is commonly used for vaccines against pneumococcal infections.

Given these details, the vaccine is likely targeting Streptococcus pneumoniae. Here's why:

- **Streptococcus pneumoniae** is a common cause of bacterial pneumonia and other infections in children.
- The conjugate vaccine (polyribosylribitol phosphate toxoid) targets this pathogen by inducing an immune response against the polysaccharide component, which is not easily immunogenic on its own.

The other options are less likely:

- **Neisseria meningitidis** and **Haemophilus influenzae** are also causes of bacterial infections in children but are typically targeted by different vaccines (meningococcal conjugate vaccine for N. meningitidis, Hib vaccine for Haemophilus influenzae type b).
- **Bordetella pertussis**, the causative agent of whooping cough, is usually targeted by a pertussis vaccine that contains diphtheria toxoid.

Therefore, considering the conjugation method and the typical targets of such vaccines, the most likely pathogen this vaccine would provide immunity against is Streptococcus pneumoniae.